Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295836794> ?p ?o ?g. }
Showing items 1 to 55 of
55
with 100 items per page.
- W4295836794 endingPage "S1267" @default.
- W4295836794 startingPage "S1267" @default.
- W4295836794 abstract "Hand-foot syndrome (HFS) and Hand Foot Skin Reaction (HFSR) are common toxicities of several systemic cancer treatments. Multikinase inhibitor- induced HFSR is distinguished from chemotherapy-induced HFS in terms of pathogenesis, symptomatology, and treatment. Multiple trials have investigated the efficacy of preventive strategies such as COX-inhibitors, pyridoxine and urea cream, however, no consensus has been made. This meta-analysis evaluated data from high quality trials to provide strong evidence in forming recommendations to prevent systemic cancer therapy-induced HFS/HFSR. A systematic search of Pubmed, Embase, Cochrane, clinical trials databases and hand searching were utilized to identify randomized trials (RCTs) investigating prophylactic strategies for HFS/HFSR in cancer patients receiving systemic treatment. Trials published until August 2021 were included. Using the random effects model, pooled odds ratios were calculated for rates of all-grade and severe HFS/HFSR. Subgroup analysis based on type of cancer treatment given was done. Sixteen RCTs were included (N=2814). For all-grade HFS/HFSR, celecoxib (OR 0.52,95%CI 0.32-0.85, p=0.009) and urea cream (OR 0.48,95%CI 0.39-0.60, p<0.00001) both showed statistically significant risk reduction. Celecoxib was effective in preventing HFS in patients who received capecitabine (50.5% vs 65%, p=0.05), while urea cream was effective in both capecitabine HFS (22.3% vs 39.5%,p=0.02) and sorafenib-induced HFSR (54.9% vs 71.4%,p<0.00001). Pyridoxine at higher doses showed a trend towards benefit in preventing all grade HFS (69.6% vs 74.1%, p=0.23). Urea cream and celecoxib are effective in preventing all-grade and moderate to severe grade HFS/HFSR in patients receiving systemic cancer treatment. Our study provides evidence that celecoxib can be more effective for capecitabine-induced HFS and urea cream for sorafenib-induced HFSR. Studies investigating optimal dosing for celecoxib and urea cream are recommended. There is inadequate evidence to make recommendations regarding pyridoxine." @default.
- W4295836794 created "2022-09-15" @default.
- W4295836794 creator A5051614801 @default.
- W4295836794 creator A5052993102 @default.
- W4295836794 date "2022-09-01" @default.
- W4295836794 modified "2023-09-28" @default.
- W4295836794 title "1579P Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: A meta-analysis of randomized controlled trials" @default.
- W4295836794 doi "https://doi.org/10.1016/j.annonc.2022.07.1672" @default.
- W4295836794 hasPublicationYear "2022" @default.
- W4295836794 type Work @default.
- W4295836794 citedByCount "0" @default.
- W4295836794 crossrefType "journal-article" @default.
- W4295836794 hasAuthorship W4295836794A5051614801 @default.
- W4295836794 hasAuthorship W4295836794A5052993102 @default.
- W4295836794 hasConcept C121608353 @default.
- W4295836794 hasConcept C126322002 @default.
- W4295836794 hasConcept C141071460 @default.
- W4295836794 hasConcept C143998085 @default.
- W4295836794 hasConcept C156957248 @default.
- W4295836794 hasConcept C168563851 @default.
- W4295836794 hasConcept C2776467144 @default.
- W4295836794 hasConcept C2777909004 @default.
- W4295836794 hasConcept C526805850 @default.
- W4295836794 hasConcept C71924100 @default.
- W4295836794 hasConcept C95190672 @default.
- W4295836794 hasConceptScore W4295836794C121608353 @default.
- W4295836794 hasConceptScore W4295836794C126322002 @default.
- W4295836794 hasConceptScore W4295836794C141071460 @default.
- W4295836794 hasConceptScore W4295836794C143998085 @default.
- W4295836794 hasConceptScore W4295836794C156957248 @default.
- W4295836794 hasConceptScore W4295836794C168563851 @default.
- W4295836794 hasConceptScore W4295836794C2776467144 @default.
- W4295836794 hasConceptScore W4295836794C2777909004 @default.
- W4295836794 hasConceptScore W4295836794C526805850 @default.
- W4295836794 hasConceptScore W4295836794C71924100 @default.
- W4295836794 hasConceptScore W4295836794C95190672 @default.
- W4295836794 hasLocation W42958367941 @default.
- W4295836794 hasOpenAccess W4295836794 @default.
- W4295836794 hasPrimaryLocation W42958367941 @default.
- W4295836794 hasRelatedWork W139760217 @default.
- W4295836794 hasRelatedWork W140910456 @default.
- W4295836794 hasRelatedWork W2003938723 @default.
- W4295836794 hasRelatedWork W2030987066 @default.
- W4295836794 hasRelatedWork W2047967234 @default.
- W4295836794 hasRelatedWork W2361436392 @default.
- W4295836794 hasRelatedWork W2366407726 @default.
- W4295836794 hasRelatedWork W2439875401 @default.
- W4295836794 hasRelatedWork W2619461160 @default.
- W4295836794 hasRelatedWork W2765302917 @default.
- W4295836794 hasVolume "33" @default.
- W4295836794 isParatext "false" @default.
- W4295836794 isRetracted "false" @default.
- W4295836794 workType "article" @default.